Tucidinostat Plus Apatinib for Advanced Osteosarcoma
This phase II study was designed to assess the efficacy and safety of the combination of Apatinib, Tucidinostat (chidamide), a histone deacetylase inhibitor in relapsed or refractory osteosarcoma patients.
Osteosarcoma
DRUG: Tucidinostat, Apatinib
6-month progression-free survival rate, The proportion of patients who did not experience disease progression or die from disease progression within 6 months from the treatment, 6 months
Progression-free survival(PFS), Time from treatment until disease progression or death, 2 years|Objective Response Rate（ORR）, Objective Response Rate（ORR）by RECIST 1.1,the total proportion of patients with complete response（CR）, partial response（PR）, 2 years|Disease Control Rate （DCR）, the total proportion of patients with complete response（CR）, partial response（PR）and stable disease（SD）, 2 years|Overall survival(OS), Time from treatment until death from any cause, 2 years
This phase II study was designed to assess the efficacy and safety of the combination of Apatinib, Tucidinostat (chidamide), a histone deacetylase inhibitor in relapsed or refractory osteosarcoma patients.